Saroj Verma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Saroj Verma has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Rajiv Kumar Tonk
Department of Pharmaceutical Chemistry, Delhi Pharmaceutical Sciences & Research University, Delhi, 110017, India
6 shared publications Vaishali M. Patil
Charak School of Pharmacy, Chaudhary Charan Singh University, Meerut, Uttar Pradesh, India
5 shared publicationsUma Agarwal
Department of Pharmaceutical Chemistry, Delhi Pharmaceutical Sciences & Research University, Delhi, India
4 shared publications- Uma Agarwal
Department of Pharmaceutical Chemistry, Delhi Pharmaceutical Sciences & Research University, Delhi, 110017, India
4 shared publications Arzoo Pannu
School of Pharmacy & Research, Dev Bhoomi Uttarakhand University, Dehradun, 248007, India
2 shared publicationsSwati Paliwal
Department of Pharmaceutical Chemistry, Delhi Pharmaceutical Sciences & Research University, Delhi, 110017, India
2 shared publications
Latest Publications
- 31 August 2026
- Published by Bentham Science Publishers Ltd. in Current Nutraceuticals
- Vol. 07 (1) , 1-22
Advancing Disease Prevention Through Nutrition: Evidence, Awareness, and Strategic Improvements
Introduction: Balance nutrition is required for maintaining physiological homeostasis and reducing the risk of diseases. Beyond their nutritional role, increasing evidence highlights the therapeutic and pharmacological importance of nutrients in disease prevention and management. However, fragmented research across nutrition, pharmacology, and public health highlights the critical need for a unified view of nutrient function. Methodology: This narrative review evaluated scientific literature published between 1998 and 2026 using PubMed, SCOPUS, and Google Scholar databases. Keywords included “essential nutrients,” “therapeutic nutrition,” “micronutrients,” “omega-3 fatty acids,” “vitamin D,” “vitamin C,” “iron,” “oxidative stress,” and “immune modulation.” Articles were selected based on relevance, scientific quality, and contribution to understanding physiological, therapeutic, and pharmacological roles of nutrients. Results: A literature review showed that omega-3 fatty acids are responsible for improving cardiovascular, lung, and gut health via anti-inflammatory biochemical pathways. Vitamin D is linked to impaired immunity and cognitive/bone decline; iron and B12 to anemia and neurological dysfunction; and iodine/selenium to thyroid malfunction. Nutritional deficiencies also associated with osteoporosis risk, liver dysfunction, pancreatic disorders, and kidney and other critical disease progression. Discussion: The manuscript highlights the important role of nutrients in driving antioxidant defense, immune modulation, tissue repair, and supporting other biological health. However, definitive clinical conclusions remain unclear. Comparison of reported data is limited by variations in study populations, inconsistent nutrient dosages, and heterogeneous methods across the literature reports. Conclusion: Essential nutrients play a critical role in maintaining physiological health. Understanding the role of nutrient therapeutics within clinical and public health frameworks represents a necessary shift to improve long-term health and prevent diseases.
- 31 August 2026
- Published by Bentham Science Publishers Ltd. in Current Nutraceuticals
- Vol. 07 (1) , 1-22
Advancing Disease Prevention Through Nutrition: Evidence, Awareness, and Strategic Improvements
Introduction: Balance nutrition is required for maintaining physiological homeostasis and reducing the risk of diseases. Beyond their nutritional role, increasing evidence highlights the therapeutic and pharmacological importance of nutrients in disease prevention and management. However, fragmented research across nutrition, pharmacology, and public health highlights the critical need for a unified view of nutrient function. Methodology: This narrative review evaluated scientific literature published between 1998 and 2026 using PubMed, SCOPUS, and Google Scholar databases. Keywords included “essential nutrients,” “therapeutic nutrition,” “micronutrients,” “omega-3 fatty acids,” “vitamin D,” “vitamin C,” “iron,” “oxidative stress,” and “immune modulation.” Articles were selected based on relevance, scientific quality, and contribution to understanding physiological, therapeutic, and pharmacological roles of nutrients. Results: A literature review showed that omega-3 fatty acids are responsible for improving cardiovascular, lung, and gut health via anti-inflammatory biochemical pathways. Vitamin D is linked to impaired immunity and cognitive/bone decline; iron and B12 to anemia and neurological dysfunction; and iodine/selenium to thyroid malfunction. Nutritional deficiencies also associated with osteoporosis risk, liver dysfunction, pancreatic disorders, and kidney and other critical disease progression. Discussion: The manuscript highlights the important role of nutrients in driving antioxidant defense, immune modulation, tissue repair, and supporting other biological health. However, definitive clinical conclusions remain unclear. Comparison of reported data is limited by variations in study populations, inconsistent nutrient dosages, and heterogeneous methods across the literature reports. Conclusion: Essential nutrients play a critical role in maintaining physiological health. Understanding the role of nutrient therapeutics within clinical and public health frameworks represents a necessary shift to improve long-term health and prevent diseases.
- 1 March 2026
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 26 (2)
Pathogens Association with Alzheimer Disease: Emerging Concepts and New Perspectives
Alzheimer’s Disease (AD) represents a significant global health challenge, distinguished by a complex pathology that involves the accumulation of abnormal proteins in the brain, leading to neuronal loss and brain atrophy. Recent research has indicated a potential association between various pathogens and the development of AD, suggesting that infectious pathogens may play a role in its pathology. The study focuses on the exploration of pathogens linked to AD. It aims to enhance the understanding of the disease's etiopathogenesis, which refers to the causes and development of the condition. The findings from this analysis have the potential to contribute to improved diagnostic methods and treatment strategies for AD. Overall, the manuscript highlights the importance of exploring infectious pathogens relating to neurodegenerative disorders. This comprehensive literature review was conducted using databases such as PubMed and Scopus, focusing on research published up to March 2025..Articles were searched based on keywords related to reviews and research exploring the association/link between different pathogens and AD, emerging interventions, preventive strategies, and limitations in study design. This study indicates that various viruses, bacteria, and fungi are significant contributors to the condition, while parasites and prions play a lesser role. Notably, the variability in pathogen species among patients could provide insights into the evolution and severity of clinical symptoms associated with the disease. Additionally, some studies propose that after modification, certain fungi may actually reduce the amyloid burden in Alzheimer's patients. However, it is crucial to emphasize that there is currently no definitive evidence supporting the notion that treating infections alone can prevent or cure AD. The prevention and treatment of pathogens, including viruses, bacteria, and fungi, as well as infectious prions, may play a significant role in reducing the risk of AD. Effective management of these pathogens can help to control and prevent further damage in individuals who have already been diagnosed with AD. There is a pressing need for additional pre-clinical and clinical research to deepen the understanding of the pathophysiological connections between pathogens and AD.
- 1 March 2026
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 26 (2)
Pathogens Association with Alzheimer Disease: Emerging Concepts and New Perspectives
Alzheimer’s Disease (AD) represents a significant global health challenge, distinguished by a complex pathology that involves the accumulation of abnormal proteins in the brain, leading to neuronal loss and brain atrophy. Recent research has indicated a potential association between various pathogens and the development of AD, suggesting that infectious pathogens may play a role in its pathology. The study focuses on the exploration of pathogens linked to AD. It aims to enhance the understanding of the disease's etiopathogenesis, which refers to the causes and development of the condition. The findings from this analysis have the potential to contribute to improved diagnostic methods and treatment strategies for AD. Overall, the manuscript highlights the importance of exploring infectious pathogens relating to neurodegenerative disorders. This comprehensive literature review was conducted using databases such as PubMed and Scopus, focusing on research published up to March 2025..Articles were searched based on keywords related to reviews and research exploring the association/link between different pathogens and AD, emerging interventions, preventive strategies, and limitations in study design. This study indicates that various viruses, bacteria, and fungi are significant contributors to the condition, while parasites and prions play a lesser role. Notably, the variability in pathogen species among patients could provide insights into the evolution and severity of clinical symptoms associated with the disease. Additionally, some studies propose that after modification, certain fungi may actually reduce the amyloid burden in Alzheimer's patients. However, it is crucial to emphasize that there is currently no definitive evidence supporting the notion that treating infections alone can prevent or cure AD. The prevention and treatment of pathogens, including viruses, bacteria, and fungi, as well as infectious prions, may play a significant role in reducing the risk of AD. Effective management of these pathogens can help to control and prevent further damage in individuals who have already been diagnosed with AD. There is a pressing need for additional pre-clinical and clinical research to deepen the understanding of the pathophysiological connections between pathogens and AD.
- Open Access
- 19 December 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (1) , 5
In Silico Investigation of Amidine-Based BACE-1 Inhibitors Against Alzheimer’s Disease: SAR, Pharmacokinetics, Molecular Docking and Dynamic Simulations
Background/Objective: Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β plaques, derived from the amyloid precursor protein through sequential cleavage by β-secretase 1 (BACE-1) and γ-secretase. BACE-1 is therefore a key drug target for designing of selective inhibitors to avoid off-target effects associated with BACE-2 inhibition. The objective of this study was to design novel BACE-1 inhibitors using a structure-based drug design approach. Methods: A focused compound library was designed based on the SAR of N-(4-fluorophenyl)formamide derivatives. In silico ADME predictions were performed to assess pharmacokinetic suitability. Compounds showing favorable ADME profiles were subjected to molecular docking against the BACE-1 enzyme. The top-scoring hit, compound 9.7 (−5.48 (kcal/mol), was further evaluated using a 200 ns MD simulation to assess the stability of its binding interactions with BACE-1. Results: Designed compounds indicated acceptable physicochemical and ADME characteristics. Molecular docking identified compound 9.7 as exhibiting favorable binding interactions with binding pocket residues of BACE-1. The 200 ns MD simulation further confirmed the stability of the docked complex. MD simulations confirmed that 9.7 forms stable interactions with the catalytic residue ASP32 and key hydrophobic residues TRP115 and PHE108 of BACE-1. These important interactions are absent in the reference compound verubecestat. Conclusions: The multi-step computational analysis suggests that compound 9.7 is a promising and selective BACE-1 inhibitor. Its favorable ADME profile, favorable docking interactions, and stable MD simulation behavior highlight its potential as a hit compound for further optimization in the development of anti-Alzheimer’s agents.
- 19 December 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (1) , 5
Open AccessIn Silico Investigation of Amidine-Based BACE-1 Inhibitors Against Alzheimer’s Disease: SAR, Pharmacokinetics, Molecular Docking and Dynamic Simulations
Background/Objective: Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β plaques, derived from the amyloid precursor protein through sequential cleavage by β-secretase 1 (BACE-1) and γ-secretase. BACE-1 is therefore a key drug target for designing of selective inhibitors to avoid off-target effects associated with BACE-2 inhibition. The objective of this study was to design novel BACE-1 inhibitors using a structure-based drug design approach. Methods: A focused compound library was designed based on the SAR of N-(4-fluorophenyl)formamide derivatives. In silico ADME predictions were performed to assess pharmacokinetic suitability. Compounds showing favorable ADME profiles were subjected to molecular docking against the BACE-1 enzyme. The top-scoring hit, compound 9.7 (−5.48 (kcal/mol), was further evaluated using a 200 ns MD simulation to assess the stability of its binding interactions with BACE-1. Results: Designed compounds indicated acceptable physicochemical and ADME characteristics. Molecular docking identified compound 9.7 as exhibiting favorable binding interactions with binding pocket residues of BACE-1. The 200 ns MD simulation further confirmed the stability of the docked complex. MD simulations confirmed that 9.7 forms stable interactions with the catalytic residue ASP32 and key hydrophobic residues TRP115 and PHE108 of BACE-1. These important interactions are absent in the reference compound verubecestat. Conclusions: The multi-step computational analysis suggests that compound 9.7 is a promising and selective BACE-1 inhibitor. Its favorable ADME profile, favorable docking interactions, and stable MD simulation behavior highlight its potential as a hit compound for further optimization in the development of anti-Alzheimer’s agents.
- 27 November 2025
- Published by Elsevier in Drug Discovery Today
- Vol. 31 (1) , 104561
Pharmacogenomics and mutation informatics: correlation of NAT2 mutations and isoniazid acetylation rate
- 27 November 2025
- Published by Elsevier in Drug Discovery Today
- Vol. 31 (1) , 104561
Pharmacogenomics and mutation informatics: correlation of NAT2 mutations and isoniazid acetylation rate
- 3 October 2025
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 24 (7) , 1-30
Pathological Insights into Neurodegenerative and Neurodevelopmental Disorders: Perspectives for the Development of Novel Treatment Approaches
Neurodegenerative and neurodevelopmental disorders represent a significant global health burden, characterized by progressive neuronal dysfunction and loss. Both diseases, despite their diverse etiologies and mechanisms, share a complex interplay of genetic, environmental, and biological factors. Neurodegenerative diseases are caused by multiple factors, including aging, mitochondrial dysfunction, oxidative stress, inflammation, genetic mutations, and protein misfolding. In contrast, neurodevelopmental disorders are primarily influenced by epigenetic alterations, neurotransmitter imbalances, early brain damage, environmental factors, and genetic variations. Despite extensive research, effective treatments remain unavailable due to the complexity of their pathologies and the biochemical pathways involved. A deep understanding of the complexities and individual differences associated with these disorders is crucial for developing effective treatments. In this background, this review provides a comprehensive overview of neurodegenerative and neurodevelopmental disorders, including their clinical symptoms, etiology, pathogenesis, underlying mechanisms, potential drug targets, reported drugs, advanced treatment options, and challenges in the drug discovery process. This comprehensive literature review was conducted using databases such as PubMed and Scopus, focusing on research published up to April 2025. By understanding the complexities of these disorders, researchers can develop novel therapeutic approaches, including potential drugs and advanced treatment methods, to mitigate their devastating impact.
- 3 October 2025
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 24 (7) , 1-30
Pathological Insights into Neurodegenerative and Neurodevelopmental Disorders: Perspectives for the Development of Novel Treatment Approaches
Neurodegenerative and neurodevelopmental disorders represent a significant global health burden, characterized by progressive neuronal dysfunction and loss. Both diseases, despite their diverse etiologies and mechanisms, share a complex interplay of genetic, environmental, and biological factors. Neurodegenerative diseases are caused by multiple factors, including aging, mitochondrial dysfunction, oxidative stress, inflammation, genetic mutations, and protein misfolding. In contrast, neurodevelopmental disorders are primarily influenced by epigenetic alterations, neurotransmitter imbalances, early brain damage, environmental factors, and genetic variations. Despite extensive research, effective treatments remain unavailable due to the complexity of their pathologies and the biochemical pathways involved. A deep understanding of the complexities and individual differences associated with these disorders is crucial for developing effective treatments. In this background, this review provides a comprehensive overview of neurodegenerative and neurodevelopmental disorders, including their clinical symptoms, etiology, pathogenesis, underlying mechanisms, potential drug targets, reported drugs, advanced treatment options, and challenges in the drug discovery process. This comprehensive literature review was conducted using databases such as PubMed and Scopus, focusing on research published up to April 2025. By understanding the complexities of these disorders, researchers can develop novel therapeutic approaches, including potential drugs and advanced treatment methods, to mitigate their devastating impact.
- 18 August 2025
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 17 (16) , 1945-1957
Multitarget 8-methoxypsoralens against Alzheimer’s disease: extraction, synthesis, in vitro and in silico studies
Alzheimer's disease poses a serious global health challenge, and there is an urgent need for novel therapeutic agents, as existing drugs have limited efficacy and notable adverse effects. Chromenones, known for their diverse biological activities, have emerged as promising drug candidates for AD treatment due to their capacity to target multiple enzymes. In this study, investigated the chromenone derivative 8-methoxypsoralen (8-MOP) as a potential multi-target inhibitor of key AD targets, highlighting the importance of the scaffold in target-based drug design. 8-MOP, a phytochemical extracted and isolated from parsley leaves, was utilized to synthesize new derivatives, which were then screened against enzymes involved in AD progression (BACE1, AChE, BuChE) and targets involved in oxidative pathways (DPPH, NO). In support of the in vitro activity, in silico ADMET predictions and docking experiments were performed. Among the synthesized compounds, 3d and 3e demonstrated significant inhibitory effects against the chosen targets, exhibiting IC50 values between 5.8 ± 0.13 μM and 13 ± 0.12 μM. Furthermore, the docking experiments showed important binding interactions of these compounds with BACE1, AChE, and BuChE. The study demonstrates the potential of 8-MOP derivatives for targeting AD drug targets.
- 18 August 2025
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 17 (16) , 1945-1957
Multitarget 8-methoxypsoralens against Alzheimer’s disease: extraction, synthesis, in vitro and in silico studies
Alzheimer's disease poses a serious global health challenge, and there is an urgent need for novel therapeutic agents, as existing drugs have limited efficacy and notable adverse effects. Chromenones, known for their diverse biological activities, have emerged as promising drug candidates for AD treatment due to their capacity to target multiple enzymes. In this study, investigated the chromenone derivative 8-methoxypsoralen (8-MOP) as a potential multi-target inhibitor of key AD targets, highlighting the importance of the scaffold in target-based drug design. 8-MOP, a phytochemical extracted and isolated from parsley leaves, was utilized to synthesize new derivatives, which were then screened against enzymes involved in AD progression (BACE1, AChE, BuChE) and targets involved in oxidative pathways (DPPH, NO). In support of the in vitro activity, in silico ADMET predictions and docking experiments were performed. Among the synthesized compounds, 3d and 3e demonstrated significant inhibitory effects against the chosen targets, exhibiting IC50 values between 5.8 ± 0.13 μM and 13 ± 0.12 μM. Furthermore, the docking experiments showed important binding interactions of these compounds with BACE1, AChE, and BuChE. The study demonstrates the potential of 8-MOP derivatives for targeting AD drug targets.
- 1 July 2025
- Published by Springer Nature in Phytochemistry Reviews
- Vol. 25 (1) , 643-689
A comprehensive review of supernatural coriander herb (Coriandrum sativum): phytochemical insights, pharmacological potential and future perspective
- 1 July 2025
- Published by Springer Nature in Phytochemistry Reviews
- Vol. 25 (1) , 643-689
A comprehensive review of supernatural coriander herb (Coriandrum sativum): phytochemical insights, pharmacological potential and future perspective
- 1 November 2024
- Published by American Chemical Society (ACS) in ACS Chemical Health & Safety
- Vol. 31 (6) , 444-467
Critical Review of Biomedical Waste Management for Future Pandemics: Pharmaceutical Perspective
During the pandemic, biomedical waste (BMW) management was reported as a global problem. World Health Organization has also stressed that COVID-19 resulted in the production of tens of thousands of tons of BMW. It includes waste from hospitals, research laboratories, pharmaceutical industry, etc., and among them, pharmaceutical waste has a major effect on the ecosystem. It includes waste generated during diagnosis, research activities, immunization, and treatment, such as vials, bottles, gloves, masks, needles, expired/unused/spilled/contaminated drugs, radioactive material, pharmacological waste, etc. Timely and precise management of BMW is a vital issue, and the present manuscript aims to provide a comprehensive overview of BMW with a major focus on pharmaceutical waste, their types, points of entry, and its management using pyrolysis, nanotechnologies, etc. Available guidelines and challenges associated with the management technologies have been reviewed, and we have proposed a practical framework suggesting the role of government agencies and the pharmaceutical industry and expected outcomes from the suggested techniques in stepwise manner. Besides various developments in the pharmaceutical field, there is requirement to develop and implement environmentally friendly approaches for BMW disposal to benefit the community.
- 1 November 2024
- Published by American Chemical Society (ACS) in ACS Chemical Health & Safety
- Vol. 31 (6) , 444-467
Critical Review of Biomedical Waste Management for Future Pandemics: Pharmaceutical Perspective
During the pandemic, biomedical waste (BMW) management was reported as a global problem. World Health Organization has also stressed that COVID-19 resulted in the production of tens of thousands of tons of BMW. It includes waste from hospitals, research laboratories, pharmaceutical industry, etc., and among them, pharmaceutical waste has a major effect on the ecosystem. It includes waste generated during diagnosis, research activities, immunization, and treatment, such as vials, bottles, gloves, masks, needles, expired/unused/spilled/contaminated drugs, radioactive material, pharmacological waste, etc. Timely and precise management of BMW is a vital issue, and the present manuscript aims to provide a comprehensive overview of BMW with a major focus on pharmaceutical waste, their types, points of entry, and its management using pyrolysis, nanotechnologies, etc. Available guidelines and challenges associated with the management technologies have been reviewed, and we have proposed a practical framework suggesting the role of government agencies and the pharmaceutical industry and expected outcomes from the suggested techniques in stepwise manner. Besides various developments in the pharmaceutical field, there is requirement to develop and implement environmentally friendly approaches for BMW disposal to benefit the community.
- 30 July 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 111, 129912
Chromenone: An emerging scaffold in anti-Alzheimer drug discovery
- 30 July 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 111, 129912
Chromenone: An emerging scaffold in anti-Alzheimer drug discovery